{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T08:00:23Z","timestamp":1789545623080,"version":"build-2803163510"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T00:00:00Z","timestamp":1656979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","award":["NCT02969525"],"award-info":[{"award-number":["NCT02969525"]}],"id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","award":["NCT03347110"],"award-info":[{"award-number":["NCT03347110"]}],"id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Costello Medical"},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Evaluate effects of long-term bimekizumab treatment on patient-reported outcome (PRO) measures, symptoms and the impact of PsA on patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients with active PsA were enrolled into BE ACTIVE, a 48-week randomised controlled trial (NCT02969525). After Week 48, patients could enter a 104-week open-label extension (NCT03347110), receiving bimekizumab 160\u2009mg every four weeks. PRO measures assessed included arthritis pain visual analogue scale (VAS), PsA Impact of Disease (PsAID)-9, 36-Item Short Form Survey (SF-36) and HAQ-Disability Index (HAQ-DI). Results were analysed as mean (S.E.M.) changes from baseline (CfB) from Week 0 to the end of the open-label extension (3\u2009years) and as percentage of patients reaching patient-acceptable symptom state (PASS) for global impact (PsAID-9 total score \u22644) and normal function (HAQ-DI total score &amp;lt;0.5). Non-responder imputation was applied to missing binary outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In 206 patients (mean age 49.3\u2009years, 51.0% male), completion rate was high; 161 (78.2%) patients completed Week 152. Bimekizumab treatment was associated with long-term sustained improvements in pain [arthritis pain VAS CfB; Week 48: \u221229.9 (1.9); Week 152: \u221232.0 (1.9)] and fatigue [PsAID-9 fatigue CfB; \u22122.4 (0.2); \u22122.7 (0.2)]. High percentages of patients achieved acceptable symptom state (PsAID-9 PASS: 75.2%; 65.0%) and normalised function (HAQ-DI &amp;lt;0.5: 49.0%; 46.1%). Improvements in patient global assessment and SF-36 Physical Component Summary were also sustained.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Bimekizumab treatment was associated with long-term sustained improvements in pain and fatigue, reducing overall impact of PsA on patients. Physical function and quality of life improved up to 3\u2009years.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration<\/jats:title>\n                  <jats:p>ClinicalTrials.gov, https:\/\/clinicaltrials.gov, NCT02969525, NCT03347110.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keac353","type":"journal-article","created":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T13:47:00Z","timestamp":1657028820000},"page":"617-628","source":"Crossref","is-referenced-by-count":13,"title":["Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: results from BE ACTIVE"],"prefix":"10.1093","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip J","family":"Mease","sequence":"first","affiliation":[{"name":"Swedish Medical Center\/Providence St. Joseph Health and University of Washington , Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Asahina","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Jikei University School of Medicine , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafna D","family":"Gladman","sequence":"additional","affiliation":[{"name":"Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Institute of Medical Science, University of Toronto , Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, University of Occupational and Environmental Health , Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7531-4125","authenticated-orcid":false,"given":"William","family":"Tillett","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Pharmacology, University of Bath , Bath"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Ink","sequence":"additional","affiliation":[{"name":"UCB Pharma , Slough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Assudani","sequence":"additional","affiliation":[{"name":"UCB Pharma , Slough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"de la Loge","sequence":"additional","affiliation":[{"name":"UCB Pharma , Braine l\u2019Alleud, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Coarse","sequence":"additional","affiliation":[{"name":"UCB Pharma , Raleigh, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Eells","sequence":"additional","affiliation":[{"name":"UCB Pharma , Slough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Gossec","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d'Epid\u00e9miologie et de Sant\u00e9 Publique"},{"name":"Rheumatology Department, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, AP-HP.Sorbonne Universit\u00e9 , Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,7,5]]},"reference":[{"key":"2023020117304197200_keac353-B1","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/1744666X.2018.1468252","article-title":"Quality of life in psoriatic arthritis","volume":"14","author":"Gudu","year":"2018","journal-title":"Expert Rev Clin. Immunol"},{"key":"2023020117304197200_keac353-B2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.semarthrit.2017.05.010","article-title":"The psychosocial burden of psoriatic arthritis","volume":"47","author":"Husni","year":"2017","journal-title":"Semin. Arthritis Rheum"},{"key":"2023020117304197200_keac353-B3","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/1529-0131(200104)45:2<151::AID-ANR168>3.0.CO;2-T","article-title":"Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis","volume":"45","author":"Husted","year":"2001","journal-title":"Arthritis Care Res"},{"key":"2023020117304197200_keac353-B4","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/rheumatology\/ker365","article-title":"Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone","volume":"51","author":"Rosen","year":"2012","journal-title":"Rheumatology"},{"key":"2023020117304197200_keac353-B5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1477-7525-7-25","article-title":"The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people","volume":"7","author":"Salaffi","year":"2009","journal-title":"Health Qual Life Outcomes"},{"key":"2023020117304197200_keac353-B6","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41572-021-00293-y","article-title":"Psoriatic arthritis","volume":"7","author":"FitzGerald","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"2023020117304197200_keac353-B7","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1136\/annrheumdis-2014-205207","article-title":"A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative","volume":"73","author":"Gossec","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2023020117304197200_keac353-B8","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.rdc.2016.01.002","article-title":"Patient-reported outcomes in psoriatic arthritis","volume":"42","author":"Orbai","year":"2016","journal-title":"Rheum Dis Clin North Am"},{"key":"2023020117304197200_keac353-B9","doi-asserted-by":"crossref","first-page":"i29","DOI":"10.1093\/rheumatology\/kez305","article-title":"Assessment of the many faces of PsA: single and composite measures in PsA clinical trials","volume":"59","author":"McGagh","year":"2020","journal-title":"Rheumatology"},{"key":"2023020117304197200_keac353-B10","doi-asserted-by":"crossref","first-page":"e001240","DOI":"10.1136\/rmdopen-2020-001240","article-title":"Relationship of pain and fatigue with health-related quality of life and work in patients with psoriatic arthritis on TNFi: results of a multi-national real-world study","volume":"6","author":"Conaghan","year":"2020","journal-title":"RMD Open"},{"key":"2023020117304197200_keac353-B11","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1136\/ard.2008.098202","article-title":"Occurrence and correlates of fatigue in psoriatic arthritis","volume":"68","author":"Husted","year":"2009","journal-title":"Ann Rheum. Dis"},{"key":"2023020117304197200_keac353-B12","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s10067-015-3035-6","article-title":"The prevalence of severe fatigue in rheumatic diseases: an international study","volume":"35","author":"Overman","year":"2016","journal-title":"Clin Rheumatol"},{"key":"2023020117304197200_keac353-B13","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s10067-006-0298-y","article-title":"A comparative evaluation of quality of life and life satisfaction in patients with psoriatic and rheumatoid arthritis","volume":"26","author":"Borman","year":"2007","journal-title":"Clin Rheumatol"},{"key":"2023020117304197200_keac353-B14","doi-asserted-by":"crossref","first-page":"e016619","DOI":"10.1136\/bmjopen-2017-016619","article-title":"Real-world validation of the minimal disease activity index in psoriatic arthritis: an analysis from a prospective, observational, biological treatment registry","volume":"7","author":"Rahman","year":"2017","journal-title":"BMJ Open"},{"key":"2023020117304197200_keac353-B15","doi-asserted-by":"crossref","first-page":"e001321","DOI":"10.1136\/rmdopen-2020-001321","article-title":"Patient\u2019s experience of psoriatic arthritis: a conceptual model based on qualitative interviews","volume":"6","author":"Ogdie","year":"2020","journal-title":"RMD Open"},{"key":"2023020117304197200_keac353-B16","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3109\/09546634.2014.996514","article-title":"The experience of pain and redness in patients with moderate to severe plaque psoriasis","volume":"26","author":"Martin","year":"2015","journal-title":"J Dermatolog Treat"},{"key":"2023020117304197200_keac353-B17","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2023020117304197200_keac353-B18","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1136\/annrheumdis-2016-210242","article-title":"International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials","volume":"76","author":"Orbai","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023020117304197200_keac353-B19","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0140-6736(19)33161-7","article-title":"Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial","volume":"395","author":"Ritchlin","year":"2020","journal-title":"Lancet"},{"key":"2023020117304197200_keac353-B20","doi-asserted-by":"crossref","DOI":"10.1002\/art.42280","article-title":"Safety and Efficacy of Bimekizumab in Patients with Active Psoriatic Arthritis: 3-Year Results from a Phase 2b Randomized Controlled Trial and its Open-Label Extension Study","author":"Coates","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2023020117304197200_keac353-B21","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jpain.2007.09.005","article-title":"Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations","volume":"9","author":"Dworkin","year":"2008","journal-title":"J Pain"},{"key":"2023020117304197200_keac353-B22","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0304-3959(01)00349-9","article-title":"Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale","volume":"94","author":"Farrar","year":"2001","journal-title":"Pain"},{"key":"2023020117304197200_keac353-B23","doi-asserted-by":"crossref","first-page":"898","DOI":"10.3899\/jrheum.100857","article-title":"Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study","volume":"38","author":"Cauli","year":"2011","journal-title":"J Rheumatol"},{"key":"2023020117304197200_keac353-B24","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1477-7525-1-20","article-title":"The Stanford Health Assessment Questionnaire: dimensions and practical applications","volume":"1","author":"Bruce","year":"2003","journal-title":"Health Qual Life Outcomes"},{"key":"2023020117304197200_keac353-B25","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/acr.24216","article-title":"Adult measures of general health and health-related quality of life","volume":"72","author":"Busija","year":"2020","journal-title":"Arthritis Care Res"},{"key":"2023020117304197200_keac353-B26","first-page":"365","article-title":"Normalisation of physical function by infliximab in patients with RA: factors associated with normal physical function","volume":"28","author":"Nagasawa","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"2023020117304197200_keac353-B27","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.3899\/jrheum.110546","article-title":"Minimally important difference of health assessment questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance and satisfaction","volume":"38","author":"Mease","year":"2011","journal-title":"J Rheumatol"},{"key":"2023020117304197200_keac353-B28","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1136\/ard.2006.057901","article-title":"Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial","volume":"66","author":"Gladman","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"2023020117304197200_keac353-B29","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.semarthrit.2018.05.010","article-title":"Functional impairment measurement in psoriatic arthritis: Importance and challenges","volume":"48","author":"Mease","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"2023020117304197200_keac353-B30","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1136\/annrheumdis-2020-eular.4204","article-title":"AB0778 association between patient-reported outcomes and disease activity in bimekizumab-treated patients with psoriatic arthritis [abstract]","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2023020117304197200_keac353-B31","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1136\/annrheumdis-2017-211996","article-title":"Validation of the Psoriatic Arthritis Impact of Disease (PsAID) Questionnaire and its potential as a single-item outcome measure in clinical practice","volume":"77","author":"Holland","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2023020117304197200_keac353-B32","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13075-018-1610-3","article-title":"Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study","volume":"20","author":"McInnes","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2023020117304197200_keac353-B33","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s40744-020-00209-4","article-title":"Safety and efficacy of tofacitinib in patients with active psoriatic arthritis: interim analysis of OPAL balance, an open-label, long-term extension study","volume":"7","author":"Nash","year":"2020","journal-title":"Rheumatol Ther"},{"key":"2023020117304197200_keac353-B34","doi-asserted-by":"crossref","first-page":"329","DOI":"10.55563\/clinexprheumatol\/c2lbri","article-title":"Rapid and sustained improvements in patient-reported signs and symptoms with ixekizumab in biologic-naive and TNF-inadequate responder patients with psoriatic arthritis","volume":"39","author":"Orbai","year":"2021","journal-title":"Clin Exp Rheumatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keac353\/44859598\/keac353.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/2\/617\/49031709\/keac353.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/2\/617\/49031709\/keac353.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T00:40:57Z","timestamp":1675298457000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/62\/2\/617\/6631224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,5]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,7,5]]},"published-print":{"date-parts":[[2023,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keac353","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,2,1]]},"published":{"date-parts":[[2022,7,5]]}}}